PRNewsWire
14 Sept 2026, 10:45 UTC · 2h ago
Verdict
Headline takes no side. We score TYRA +0.40 across three claims.
Our read: bullish.
TYRA score
+0.40
More positive than 66% of ticker scores this week
Price reaction
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen
What the story claims
3 claims · scored −1 bearish … +1 bullish
The company will use the proceeds to advance its 'dabogratinib 3x3' development strategy across three indications: LG-UTUC, IR NMIBC, and achondroplasia.
More positive than 77% of claims this week
Tyra Biosciences has priced an underwritten offering of common stock and pre-funded warrants to raise approximately $400 million.
So whatEquity offerings typically lead to short-term share price dilution for existing shareholders.
Continue reading
5 related stories
Top 1 mover · tap to explore
More negative than 72% of claims this week
The offering is being supported by a group of new and existing institutional investors, including RA Capital Management and Janus Henderson Investors.
More positive than 55% of claims this week
Which stocks this story touches
More positive than 66% of ticker scores this week
The company is raising $400 million in capital to advance its clinical development strategy and drug discovery programs.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Reuters
4h ago
Price reaction
Expected +0.40Actual —
TYRA hasn't traded since this ran. Last close $22.03 (Sep 11); the reaction starts at the next open.
TYRA chart →
